Until now, no clear guidance has been available from any authority on a key aspect of drug applications/marketing authorizations, namely, the determination of a suitable starting point for the description of the synthesis of the active pharmaceutical ingredient (API). This paper describes, for the first time, a fully scientifically-based proposal for such guidance. It is intended as a recommendation to the International Conference on Harmonization (ICH) expert working group developing guidance with respect to the definition of the “API Starting Material” (APISM) within the Common Technical Document (CTD) initiative. The authors recommend a similar approach to be used in the ICH to define the starting point in the API synthesis, afrer which full Current Good Manufacturing Practice (cGMP) principles should apply.
This is a preview of subscription content, log in to check access.
Buy single article
Instant unlimited access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
About this article
Cite this article
Möller, H., Oldenhof, C. The Active Pharmaceutical Ingredients Starting Material (Apism) and other Materials in API Manufacture: Scientifically-Based Principles for the Common Technical Dossier. Ther Innov Regul Sci 33, 755–761 (1999). https://doi.org/10.1177/009286159903300314
- Starting material